重组白细胞A干扰素联合阿霉素。晚期实体瘤的I期研究及对肝细胞癌的意义。

Recombinant leukocyte A interferon with doxorubicin. A phase I study in advanced solid neoplasms and implications for hepatocellular carcinoma.

作者信息

Creagan E T, Long H J, Frytak S, Moertel C G

机构信息

Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905.

出版信息

Cancer. 1988 Jan 1;61(1):19-22. doi: 10.1002/1097-0142(19880101)61:1<19::aid-cncr2820610105>3.0.co;2-8.

DOI:10.1002/1097-0142(19880101)61:1<19::aid-cncr2820610105>3.0.co;2-8

PMID:2825959

Abstract

A pilot study was performed on seven patients with advanced solid neoplasms. They received recombinant leukocyte interferon A (rIFN-alpha A) 12 X 10(6) U/m2 intramuscularly daily for 5 days plus doxorubicin, 25 mg/m2 IV on day 3 of each monthly cycle (Roferon-A, Hoffman-LaRoche, Nutley, NJ). Because of side effects, the dose was not increased above the initial level. There was a striking partial response of biopsy-confirmed hepatocellular carcinoma for 6+ months along with a decrease in alpha-fetoprotein from 39,000 to 202 ng/mL. The doxorubicin dose is approximately 33% to 42% of the typical single-agent dose, thus suggesting that the clinical toxicity from these two agents is additive.

摘要

对7例晚期实体瘤患者进行了一项初步研究。他们接受重组白细胞干扰素A（rIFN-αA），剂量为12×10⁶U/m²，每日肌肉注射，共5天，同时在每个月周期的第3天静脉注射阿霉素25mg/m²（Roferon-A，霍夫曼-罗氏公司，新泽西州纳特利）。由于副作用，剂量未超过初始水平。活检证实的肝细胞癌出现了显著的部分缓解，持续6个多月，同时甲胎蛋白从39,000降至202ng/mL。阿霉素剂量约为典型单药剂量的33%至42%，因此表明这两种药物的临床毒性是相加的。